- Home
- PLUT vs CELU Comparison
PLUT vs CELU Comparison
Compare PLUT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUT
- CELU
- Stock Information
- Founded
- PLUT 2018
- CELU 2016
- Country
- PLUT Hong Kong
- CELU United States
- Employees
- PLUT N/A
- CELU N/A
- Industry
- PLUT
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- PLUT
- CELU Health Care
- Exchange
- PLUT NYSE
- CELU Nasdaq
- Market Cap
- PLUT 35.6M
- CELU 37.7M
- IPO Year
- PLUT 2025
- CELU N/A
- Fundamental
- Price
- PLUT $2.51
- CELU $2.20
- Analyst Decision
- PLUT
- CELU
- Analyst Count
- PLUT 0
- CELU 0
- Target Price
- PLUT N/A
- CELU N/A
- AVG Volume (30 Days)
- PLUT 46.3K
- CELU 91.2K
- Earning Date
- PLUT 01-01-0001
- CELU 05-08-2025
- Dividend Yield
- PLUT N/A
- CELU N/A
- EPS Growth
- PLUT N/A
- CELU N/A
- EPS
- PLUT N/A
- CELU N/A
- Revenue
- PLUT $1,435,597.00
- CELU $54,220,000.00
- Revenue This Year
- PLUT N/A
- CELU $23.29
- Revenue Next Year
- PLUT N/A
- CELU N/A
- P/E Ratio
- PLUT N/A
- CELU N/A
- Revenue Growth
- PLUT 1.42
- CELU 138.11
- 52 Week Low
- PLUT $2.10
- CELU $1.00
- 52 Week High
- PLUT $4.22
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- PLUT N/A
- CELU 57.69
- Support Level
- PLUT N/A
- CELU $1.90
- Resistance Level
- PLUT N/A
- CELU $2.47
- Average True Range (ATR)
- PLUT 0.00
- CELU 0.28
- MACD
- PLUT 0.00
- CELU 0.01
- Stochastic Oscillator
- PLUT 0.00
- CELU 68.23
About PLUT PLUTUS FINANCIAL GROUP LIMITED
Plutus Financial Group Ltd provides financial services. It mainly offers (i) securities dealings and brokerage services (ii) margin financing services and (iii) underwriting and placing services.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.